Compare State Street SPDR S&P Biotech ETF (XBI) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Energy Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B), while Energy Select Sector SPDR Fund trades at $65.09 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is far larger — about 4× State Street SPDR S&P Biotech ETF's market cap, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| XBI | XLE | |
|---|---|---|
Market Cap | $10.11B | $40.84B |
Volume | 12,903,266 | 50,409,268 |
Sector | Broad Market / Factor | — |
52-Week High | $169.55 | $65.93 |
52-Week Low | $104.99 | $42.61 |
Typical Hold Time | 38 Days | 67 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
XLE trades at $65.24, up 2.93% with strong bullish momentum from moving averages but overbought RSI signals. The energy ETF benefits from oil price surges above $100 and Middle East tensions, though futures traders bet on a 12% sector decline. Dividend yield remains modest with a $0.38 distribution scheduled for September 2026.
Outlook hinges on oil price sustainability amid geopolitical risks and Fed policy. Key risks include oil volatility and strategic reserve releases. Analysts show mixed signals with technical strength but fundamental data gaps warrant caution for energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
